Effects of Sirolimus Treatment on Fetal Hemoglobin Production and Response to SARS-CoV-2 Vaccination: A Case Report Study

Overview

Journal Hematol Rep

Publisher MDPI

Date 2023 Jul 25

PMID 37489374

Authors

Maria Rita Gamberini

Cristina Zuccato

Matteo Zurlo

Lucia Carmela Cosenza

Alessia Finotti

Roberto Gambari

Affiliations

Soon will be listed here.

Abstract

The β-thalassemias are a group of monogenic hereditary hematological disorders caused by deletions and/or mutations of the β-globin gene, leading to low or absent production of adult hemoglobin (HbA). For β-thalassemia, sirolimus has been under clinical consideration in two trials (NCT03877809 and NCT04247750). A reduced immune response to anti-SARS-CoV-2 vaccination has been reported in organ recipient patients treated with the immunosuppressant sirolimus. Therefore, there was some concern regarding the fact that monotherapy with sirolimus would reduce the antibody response after SARS-CoV-2 vaccination. In the representative clinical case reported in this study, sirolimus treatment induced the expected increase of fetal hemoglobin (HbF) but did not prevent the production of anti-SARS-CoV-2 IgG after vaccination with mRNA-1273 (Moderna). In our opinion, this case report should stimulate further studies on β-thalassemia patients under sirolimus monotherapy in order to confirm the safety (or even the positive effects) of sirolimus with respect to the humoral response to anti-SARS-CoV-2 vaccination. In addition, considering the extensive use of sirolimus for the treatment of other human pathologies (for instance, in organ transplantation, systemic lupus erythematosus, autoimmune cytopenia, and lymphangioleiomyomatosis), this case report study might be of general interest, as large numbers of patients are currently under sirolimus treatment.

References

Weatherall D . Phenotype-genotype relationships in monogenic disease: lessons from the thalassaemias. Nat Rev Genet. 2001; 2(4):245-55. DOI: 10.1038/35066048. View

Kahan B . Sirolimus: a new agent for clinical renal transplantation. Transplant Proc. 1997; 29(1-2):48-50. DOI: 10.1016/s0041-1345(96)00008-5. View

de Boer S, Berger S, Van Leer-Buter C, Kroesen B, van Baarle D, Sanders J . Enhanced Humoral Immune Response After COVID-19 Vaccination in Elderly Kidney Transplant Recipients on Everolimus Versus Mycophenolate Mofetil-containing Immunosuppressive Regimens. Transplantation. 2022; 106(8):1615-1621. PMC: 9311282. DOI: 10.1097/TP.0000000000004177. View

Prosdocimi M, Zuccato C, Cosenza L, Borgatti M, Lampronti I, Finotti A . A Rational Approach to Drug Repositioning in β-thalassemia: Induction of Fetal Hemoglobin by Established Drugs. Wellcome Open Res. 2022; 7:150. PMC: 9453112. DOI: 10.12688/wellcomeopenres.17845.2. View

Mao B, Zhang Q, Ma L, Zhao D, Zhao P, Yan P . Overview of Research into mTOR Inhibitors. Molecules. 2022; 27(16). PMC: 9413691. DOI: 10.3390/molecules27165295. View

Ji L, Xie W, Zhang Z . Efficacy and safety of sirolimus in patients with systemic lupus erythematosus: A systematic review and meta-analysis. Semin Arthritis Rheum. 2020; 50(5):1073-1080. DOI: 10.1016/j.semarthrit.2020.07.006. View

Kaeberlein T, Green A, Haddad G, Hudson J, Isman A, Nyquist A . Evaluation of off-label rapamycin use to promote healthspan in 333 adults. Geroscience. 2023; 45(5):2757-2768. PMC: 10187519. DOI: 10.1007/s11357-023-00818-1. View

Chemaitelly H, Tang P, Hasan M, Almukdad S, Yassine H, Benslimane F . Waning of BNT162b2 Vaccine Protection against SARS-CoV-2 Infection in Qatar. N Engl J Med. 2021; 385(24):e83. PMC: 8522799. DOI: 10.1056/NEJMoa2114114. View

Goldberg Y, Mandel M, Bar-On Y, Bodenheimer O, Freedman L, Haas E . Waning Immunity after the BNT162b2 Vaccine in Israel. N Engl J Med. 2021; 385(24):e85. PMC: 8609604. DOI: 10.1056/NEJMoa2114228. View

10.

Wang Q, Luo M, Xiang B, Chen S, Ji Y . The efficacy and safety of pharmacological treatments for lymphangioleiomyomatosis. Respir Res. 2020; 21(1):55. PMC: 7023761. DOI: 10.1186/s12931-020-1316-3. View

11.

Musallam K, Sankaran V, Cappellini M, Duca L, Nathan D, Taher A . Fetal hemoglobin levels and morbidity in untransfused patients with β-thalassemia intermedia. Blood. 2011; 119(2):364-7. DOI: 10.1182/blood-2011-09-382408. View

12.

Carsetti R, Agrati C, Pinto V, Gianesin B, Gamberini R, Fortini M . Premature aging of the immune system affects the response to SARS-CoV-2 mRNA vaccine in β-thalassemia: role of an additional dose. Blood. 2022; 140(15):1735-1738. PMC: 9420073. DOI: 10.1182/blood.2022017594. View

13.

Tang C, Shen A, Wei X, Li Q, Liu R, Deng H . Everolimus in de novo liver transplant recipients: a systematic review. Hepatobiliary Pancreat Dis Int. 2015; 14(5):461-9. DOI: 10.1016/s1499-3872(15)60419-2. View

14.

Tunbridge M, Perkins G, Singer J, Salehi T, Ying T, Grubor-Bauk B . Rapamycin and inulin for booster vaccine response stimulation (RIVASTIM)-rapamycin: study protocol for a randomised, controlled trial of immunosuppression modification with rapamycin to improve SARS-CoV-2 vaccine response in kidney transplant.... Trials. 2022; 23(1):780. PMC: 9477178. DOI: 10.1186/s13063-022-06634-w. View

15.

Khaibullina A, Almeida L, Wang L, Kamimura S, Wong E, Nouraie M . Rapamycin increases fetal hemoglobin and ameliorates the nociception phenotype in sickle cell mice. Blood Cells Mol Dis. 2015; 55(4):363-72. DOI: 10.1016/j.bcmd.2015.08.001. View

16.

Lechauve C, Keith J, Khandros E, Fowler S, Mayberry K, Freiwan A . The autophagy-activating kinase ULK1 mediates clearance of free α-globin in β-thalassemia. Sci Transl Med. 2019; 11(506). PMC: 7441525. DOI: 10.1126/scitranslmed.aav4881. View

17.

Sripichai O, Fucharoen S . Fetal hemoglobin regulation in β-thalassemia: heterogeneity, modifiers and therapeutic approaches. Expert Rev Hematol. 2016; 9(12):1129-1137. DOI: 10.1080/17474086.2016.1255142. View

18.

Vasquez E . Sirolimus: a new agent for prevention of renal allograft rejection. Am J Health Syst Pharm. 2000; 57(5):437-48; quiz 449-51. DOI: 10.1093/ajhp/57.5.437. View

19.

Banjongjit A, Phirom S, Phannajit J, Jantarabenjakul W, Paitoonpong L, Kittanamongkolchai W . Benefits of Switching Mycophenolic Acid to Sirolimus on Serological Response after a SARS-CoV-2 Booster Dose among Kidney Transplant Recipients: A Pilot Study. Vaccines (Basel). 2022; 10(10). PMC: 9609831. DOI: 10.3390/vaccines10101685. View

20.

Netti G, Infante B, Troise D, Mercuri S, Panico M, Spadaccino F . mTOR inhibitors improve both humoral and cellular response to SARS-CoV-2 messenger RNA BNT16b2 vaccine in kidney transplant recipients. Am J Transplant. 2022; 22(5):1475-1482. PMC: 9303518. DOI: 10.1111/ajt.16958. View